Skip to main content
PLOS One logoLink to PLOS One
. 2026 Nov 11;21(11):e0362259. doi: 10.1371/journal.pone.0362259

Molecular diversity and structural profiling of the EmrD efflux pump in multidrug-resistant uropathogenic Escherichia coli

Svala H Mahmood 1, Iman H F Alnaqshabandy 1,*
Editor: Daniel F M Monte2
PMCID: PMC13754136  PMID: 43013491

Abstract

Uropathogenic Escherichia coli (UPEC) presents a significant therapeutic challenge due to increasing multidrug resistance (MDR). While acquired resistance mechanisms are well-documented, the genetic variability of intrinsic efflux pumps like EmrD remains less characterized. This study investigated the genomic diversity and structural conservation of the EmrD transporter in ten clinical MDR isolates from the Kurdistan Region, Iraq. Isolates were screened for the emrD and β-lactamase genes, followed by emrD sequencing, phylogenetic analysis, and in silico protein modeling. Results confirmed the universal presence of emrD alongside multiple resistance genes. Phylogenetic analysis identified notable local genetic diversity, including a highly divergent lineage (DUH 11). Protein modeling mapped non-synonymous substitutions to transmembrane helices 6 and 12, regions critical for the “rocker-switch” conformational changes required for substrate translocation. These findings suggest that while EmrD is a stable component of the MDR machinery, localized genomic divergence may potentially influence efflux efficiency among clinical lineages, warranting future functional validation.

Introduction

Bacterial efflux pumps (EPs) are integral membrane transport proteins that play a crucial role in protecting bacteria against toxic compounds, including many classes of antibiotics. These pumps extrude structurally diverse substrates from the cytoplasm or periplasm into the external environment, thereby lowering intracellular drug concentrations and reducing susceptibility [1–3]. Beyond antimicrobial resistance, EPs are also involved in detoxification of metabolic by-products, maintenance of cellular homeostasis, and interactions with host tissues [4,5]. Given these multifunctional roles, efflux pumps are increasingly recognized as important contributors not only to resistance but also to bacterial adaptation and virulence.

Among multidrug resistance (MDR) efflux systems, several families have been described, including ATP-binding cassette (ABC), resistance–nodulation–division (RND), major facilitator superfamily (MFS), multidrug and toxic compound extrusion (MATE), small multidrug resistance (SMR), and more recently, the proteobacterial antimicrobial compound efflux (PACE) and AbgT families [6,7]. Members of these families share conserved structural motifs and mechanisms of energy coupling, most commonly using the proton motive force to transport substrates against their concentration gradients. The MFS, in particular, is one of the largest and most diverse transporter families, typically organized into two symmetrical bundles of transmembrane helices that facilitate the movement of chemically distinct molecules [8,9]. These pumps serve as critical defense mechanisms, utilizing the electrochemical gradient to drive the efflux of multiple drug classes while simultaneously maintaining bacterial cellular homeostasis [10]. Several high-resolution structures of MFS transporters have revealed conserved sequence motifs and a central cavity that accommodates substrates ranging from hydrophilic solutes to lipophilic antimicrobial agents [11,12].

Within this superfamily, the EmrD efflux pump of Escherichia coli (E. coli) has been studied as a prototypical MFS multidrug transporter. EmrD was the first antimicrobial carrier of this family for which a crystal structure was resolved, providing critical insights into the architecture of its 12 transmembrane helices and substrate-binding pocket [13]. Functionally, EmrD contributes to resistance against hydrophobic compounds, including uncouplers and antibiotics, by transporting them across the inner membrane [13,14]. Related systems such as EmrAB-TolC form tripartite complexes that span the entire Gram-negative envelope, yet structural and mechanistic details of EmrD and its homologues remain incompletely understood [15]. Despite advances in characterizing MFS efflux pumps, there are still substantial gaps in linking sequence variation to structural changes and functional consequences in clinically relevant bacterial strains.

Uropathogenic Escherichia coli (UPEC) is a major cause of urinary tract infection worldwide, responsible for 75% of uncomplicated and 65% of complicated cases, thereby contributing to significant global morbidity and healthcare costs [16]. Increasing resistance to commonly used antibiotics has complicated treatment of UPEC infections and underscores the importance of intrinsic resistance mechanisms, such as efflux pumps. While major efflux pumps like AcrAB-TolC are well-characterized, the emrD transporter remains a distinct variable in the E. coli resistance repertoire. Evidence from whole-genome sequencing of clinical isolates demonstrates that emrD is maintained alongside diverse resistance determinants in strains capable of causing systemic infections [17]. Consequently, characterizing genetic variation in emrD across UPEC isolates may provide important insights into the evolutionary dynamics of efflux systems, their contribution to virulence, and their potential as targets for novel therapeutic strategies.

In this study, we characterized sequence variation in the emrD efflux pump among ten clinically isolated E. coli strains to identify conserved and divergent features that may influence substrate specificity and functional activity. By integrating comparative genomic and structural analyses, we aim to advance understanding of how EmrD contributes to multidrug resistance and pathogenicity in UPEC.

Materials and methods

Bacterial strains and DNA samples

A total of ten de-identified E. coli DNA samples were obtained in January, 2025 from the archival repository of the Molecular Microbiology Laboratory, College of Science, University of Duhok. These samples originated from clinical E. coli isolates recovered during routine diagnostic procedures from patients diagnosed with urinary tract infections (UTIs) at Azadi Teaching Hospital, Duhok, Kurdistan Region, Iraq. In this Study, isolates are operationally defined as UPEC based on clinical source criteria (recovery as significant monocultures ≥105 CFU/mL from symptomatic UTI patients). Species identity was previously confirmed at the molecular level via housekeeping gene PCR and biochemically using the BD Phonex automated microbiology system during a prior master’s research project [18]. The isolates were selected for the current molecular characterization based on their extensive multidrug-resistant (MDR)profiles.

Ethical Statement: The authors had no access to information that could identify individual participants during or after data collection. All samples were fully anonymized and identified only by laboratory codes assigned during the original master’s project. The bacteria were isolated as part of routine clinical UTI treatment and diagnosis, not specifically for the purpose of research. Because this study utilized archived bacterial DNA isolates rather than direct human participation or identifiable medical records, the requirement for formal ethical approval was waived according to the institutional guidelines of the University of Duhok.

Antimicrobial susceptibility testing, previously performed using the Kirby-Bauer disk diffusion method according to CLSI guidelines, confirmed that all selected isolates (n = 10) were fully resistant to penicillins (penicillin and amoxicillin,), third-generation cephalosporins (cefotaxime, ceftriaxone, ceftazidime), fluoroquinolones (ciprofloxacin), and folate pathway inhibitors (trimethoprim-sulfamethoxazole). Phenotypic resistance to cloxacillin was also uniformly observed, which was contextualized strictly as an intrinsic, natural property of E. coli due to poor outer membrane permeability rather than an acquired resistance trait. These isolates were specifically selected to represent the most challenging clinical phenotypes in the region, serving as a targeted pilot group to characterize the genetic and structural variation of the emrD transporter within a high-resistance genomic context. This comprehensive resistance profile served as the basis for investigating the underlying genetic mechanisms, specifically the emrD efflux pump and β-lactamase genes. Genomic DNA had been extracted using the traditional chloroform–isoamyl alcohol method and stored at –20 °C until use for molecular analysis.

Molecular detection of β-Lactamase and the emrD gene

Stored genomic DNA from ten E. coli isolates was used for PCR amplification to detect selected β-lactamase genes (blaNDM, blaSHV, blaTEM, blaCTX-M-1 and blaCTX-M-9) and the multidrug efflux pump gene emrD. The primers used for β-lactamase genes detection were obtained from previous studies [19], while the emrD target primers were designed in this study; all sequences are natively summarized in Table 1. PCR reactions were carried out in 20 µL total volume containing 10 µL of 2 × PCR Master Mix (Promega, South Korea), each primer at a final concentration of 0.5 µM, 2 µL of DNA template, and nuclease-free water to the final volume. To monitor for reagent contamination and non-specific amplification, a negative non-template control (NTC; replacing DNA template with nuclease-free water) was routinely included in every PCR batch, consistently demonstrating no non-specific amplification. Amplification of β-lactamase genes was performed under the following general thermal profile: initial denaturation at 95 °C for 5 min; 35 cycles of denaturation at 94 °C for 30 s, primer-specific annealing at the temperature listed in Table 1 for 30 s, and extension at 72 °C for 60 s; followed by a final extension at 72 °C for 5 min.

Table 1. List of primers used in this study.

Target gene Primer Sequence (5’→3’) Amplicon size (bp) Annealing(℃) Reference
bla NDM F: GGTTTGGCGATCTGGTTTTC

R: CGGAATGGCTCACGATC
621 52 [19]
bla SHV F: AGCCGCTTGAGCAAATTAAAC

R: ATCCCGCAGATAAATCACCAC
713 60 [19]
bla TEM F: CATTTCCGTGTCGCCCTTATTC

R: CGTTCATCCATAGTTGCCTGAC
800 60 [19]
bla CTX-M-1 F: AAAAATCACTGCGTCAGTTCAC

R: ACAAACCGTTGGTGACGATT
867 55 [19]
bla CTX-M-9 F: TATTGGGAGTTTGAGATGGT

R: TCCTTCAACTCAGCAAAAGT
933 50 [19]
emrD F: CAGATGGCGCAAACCATTTA

R: CACAGCACGATCAACAATCC
1076 55 This study

For detection of the emrD efflux pump gene, PCR amplification was performed with the following specific program: pre-denaturation at 95 °C for 3 min; 30 cycles of denaturation at 95 °C for 1 min, annealing at 55 °C for 1 min, and extension at 72 °C for 1.5 min; followed by a final extension at 72 °C for 8 min. PCR products were separated by electrophoresis on 1% agarose gel prepared in a 1 × TBE buffer, stained with SYBR safe DNA gel stain, and visualized under UV illumination. A 100-bp DNA ladder (Thermo Fisher Scientific, South Korea) was used as a molecular size marker.

Sequence processing and alignment

Representative PCR products from the emrD gene were submitted to Macrogen Inc. (Seoul, South Korea) for Sanger sequencing using both forward and reverse primers. Raw DNA sequencing data (forward and reverse reads) were obtained for 10 strains of emrD. Sequence chromatograms were visually inspected and quality-trimmed to remove low-quality bases at the 5’ and 3’ ends using the Benchling webserver. End-trimming of primer-binding regions trimmed 31 N-terminal amino acids and 50 C-terminal amino acids, leaving residues 32–345 for analysis across all isolates. Sequences were retained only if Phred quality scores exceeded 30 (99.9% accuracy). In addition, to ensure sequence accuracy, the forward and reverse reads for each strain were aligned pairwise. A consensus sequence was generated for each of the 10 samples by resolving discrepancies between the forward and reverse strands. The ten generated consensus sequences along with the reference emrD sequence retrieved from GenBank using E. coli strain k-12 substrain MG1655 and two prototypical UPEC reference strains—CFT073 (Accession: AAN83032.1) and 536 (Accession: WP_001335494.1) were then subjected to multiple sequence alignment (MSA) using Clustal Omega v1.2.4 [20]. Inclusion of prototypical UPEC reference genomes enabled the explicit differentiation of shared UPEC background polymorphisms from local, isolate-specific substitutions. The alignment was inspected for gaps and conserved regions. Following alignment, Single Nucleotide Polymorphisms (SNPs) were identified by comparing the aligned sequences against a reference strain. The emrD gene sequences for all ten clinical isolates were deposited in the NCBI GenBank database under accession numbers (PZ196343, PZ196344, PZ196345, PZ196346, PZ196347, PZ196348, PZ196349, PZ196350, PZ196351, PZ196352).

Phylogenetic analysis

Phylogenetic relationships were analyzed using MEGA (Molecular Evolutionary Genetics Analysis) software, version 11.0. Prior to tree construction, the “Find Best DNA/Protein Models” feature in MEGA was used to determine the best-fit substitution model for the data. The model with the lowest Bayesian Information Criterion (BIC) score is considered to describe the substitution pattern the best [21]. Hasegawa-Kishino-Yano (HKY) + Gamma (G), was determined as the best fit model and was selected for analysis. A phylogenetic tree was constructed using the Maximum Likelihood (ML) method. Branch support was assessed using a bootstrap analysis with 1000 replicates.

In Silico conservation and frequency analysis

To evaluate the broader evolutionary conservation of the identified EmrD variants, a comparative analysis was performed using the NCBI Basic Local Alignment Search Tool (BLASTp). The protein sequence of the E. coli K-12 EmrD reference was used as a query against the non-redundant protein sequences (nr) database. A curated panel of 25 representative E. coli reference sequences displaying high query coverage (≥98%) and sequence identity (≥95%) across diverse pathotypes and geographic origins were retrieved. This non-redundant global dataset was used to calculate the frequency of specific amino acid substitutions (e.g., A173T and V304I) and to determine whether observed mutations occurred within conserved transmembrane helices or variable loop regions.

Results

Antibiotic resistance profiles

All ten E. coli isolates included in this study exhibited a uniform multidrug-resistant (MDR) phenotype, displaying 100% resistance to amoxicillin, cefotaxime, ceftriaxone, ceftazidime, ciprofloxacin, and trimethoprim-sulfamethoxazole. The observed resistance to third-generation cephalosporins (cefotaxime, ceftazidime) is phenotypically consistent with the production of Extended-Spectrum β-Lactamases (ESBLs), justifying the screening for blaCTX-M and blaTEM genes. Furthermore, the universal resistance to ciprofloxacin suggests the involvement of active efflux mechanisms or target site mutations, providing the rationale for sequencing the emrD multidrug efflux pump gene in these strains.

PCR amplification of the emrD gene

The PCR amplification of the emrD gene was successful for all 10 clinical E. coli isolates (DUH 01, 02, 03, 04, 05, 06, 09, 10, 11, and 21). Agarose gel electrophoresis revealed clear, single DNA bands of the expected size, 1,076 bp (corresponding to the full-length coding sequence), for all samples. No non-specific amplification or primer dimers were observed, confirming the specificity of the primers used (Fig 1).

Fig 1. PCR amplification of the emrD gene in multidrug-resistant E. coli isolates.

Fig 1

Representative 1% agarose gel electrophoresis image showing the PCR products of the emrD efflux pump gene. Lane L: 100 bp DNA Ladder (Thermo Fisher Scientific) serving as the molecular size marker. Lanes 3–12: PCR amplicons from ten clinical E. coli isolates (DUH 01 through DUH 21). All lanes exhibit a single, distinct band at the expected size of 1,076 bp (indicated by the red marker), confirming the presence of the emrD gene in all tested strains.

The primers used for both β-lactamase and efflux pump detection are detailed in Table 1. The successful amplification allowed for subsequent sequencing and phylogenetic analysis of all collected strains.

Phylogenetic analysis of EmrD transmembrane protein sequences

The phylogenetic relationship between the 10 sequenced strains (DUH series) and the reference emrD strain was analyzed based on the transmembrane protein-encoding DNA consensus sequences. The resulting tree reveals that the strains do not form a single uniform cluster but rather distribute into three distinct clades and one divergent lineage (Fig 2). The first major clade, cluster I, comprises strains that exhibit high sequence conservation with the reference. Strains DUH 09, DUH 05, DUH 06, and DUH 02 clustered tightly with the emrD Reference strain. The DUH 09 strain and the emrD Reference share a highly similar evolutionary position, with minimal branch lengths of 0.001 and 0.000, respectively. DUH 05 and DUH 06 exhibited zero divergence from their respective internal nodes (branch length 0.000), indicating identical sequences in the analyzed region relative to their immediate ancestors. DUH 02 diverged slightly within this group with a minor branch length of 0.002. A second distinct clade, cluster II, contains strains DUH 04 and DUH 10. This group is separated from the reference clade by a significant branch length of 0.012. Within this cluster, DUH 04 is more conserved (branch length 0.001), whereas DUH 10 shows greater genetic variation (branch length 0.004). The third clade, cluster III, includes strains DUH 03, DUH 21, and DUH 01. DUH 03 and DUH 21 form a closely related pair with minimal divergence (branch lengths 0.001 and 0.000, respectively). DUH 01 branches off earlier from this pair with a branch length of 0.006. Strain DUH 11 was identified as the most genetically distinct isolate in this dataset. It occupies a basal position in the tree with the longest individual terminal branch length of 0.011, suggesting it has accumulated the highest number of nucleotide substitutions relative to the other strains and the reference. Overall Diversity The scale bar indicates a genetic distance of 0.01 nucleotide substitutions per site. The topology suggests that while a subset of the local strains (Cluster I) has remained conserved relative to the reference, significant evolutionary divergence has occurred in the remaining isolates, particularly in DUH 11. However, without a genome-wide phylogenetic framework, it remains unclear whether these variations reflect evolutionary pressures acting specifically on the emrD gene or simply represent differences in the broader clonal background among these bacterial lineages.

Fig 2. Phylogenetic relationships of emrD transmembrane protein sequences.

Fig 2

Maximum Likelihood tree constructed using the Hasegawa-Kishino-Yano (HKY) substitution model with Gamma distribution, based on the alignment of emrD consensus sequences from 10 clinical isolates (DUH series) and a reference strain. Branch lengths indicate the number of nucleotide substitutions per site (scale bar = 0.01). Numbers at nodes represent bootstrap support values. The tree resolves into three primary clusters: Cluster I (comprising isolates DUH 02, DUH 05, DUH 06, DUH 09, and the reference K-12 MG1655 strain), Cluster II (comprising isolates DUH 04 and DUH 10), Cluster III (comprising isolates DUH 01, DUH 03, and DUH 21), and one divergent, basal outlier (isolate DUH 11).

Distribution of β-lactamase resistance genes

PCR screening for β-lactamase determinants revealed that all 10 clinical isolates (100%) harbored blaCTX-M-1 and blaTEM genes. None of the isolates carried blaNDM. The distribution of blaSHV and blaCTX-M-9 varied among the strains and showed partial congruence with the phylogenetic clustering of emrD (Table 2). The blaSHV gene was detected in 60% (6/10) of the isolates. Notably, both strains in the intermediate phylogenetic clade (DUH 04 and DUH 10) and the cluster III strain DUH 01 were negative for blaSHV. In contrast, the blaSHV gene was present in the majority of the reference-associated cluster (DUH 02, DUH 05, DUH 06) and the divergent outlier DUH 11. Strain DUH 06 exhibited a unique multidrug-resistance genotype, being the sole isolate to harbor blaCTX-M-9, in addition to blaCTX-M-1, blaTEM, and blaSHV.

Table 2. Genotypic profile of β-lactamase resistance genes in clinical isolates. Presence (+) or absence (-) of five major β-lactamase gene families (blaNDM, blaSHV blaTEM blaCTX-M-1 blaCTX-M-9) detected via PCR. Strains are listed corresponding to their phylogenetic identifiers.

Strain ID bla NDM bla CTX-M-1 bla CTX-M-9 bla SHV bla TEM
DUH 01 – + – – +
DUH 02 – + – + +
DUH 03 – + – + +
DUH 04 – + – – +
DUH 05 – + – + +
DUH 06 – + + + +
DUH 09 – + – – +
DUH 10 – + – – +
DUH 11 – + – + +
DUH 21 – + – + +

Amino acid substitutions and structural localization in EmrD

Translation of the nucleotide sequences into protein sequences revealed three distinct non-synonymous amino acid substitutions among the study isolates compared to the reference strain (Table 3). Structural mapping of these residues indicated that all observed mutations are located within key transmembrane helices (TMH) of the EmrD transporter (Fig 3). To assess the evolutionary significance of these changes, a comparative analysis was performed against 25 E. coli reference sequences (S1 Fig). Two mutations were identified within the sixth transmembrane helix, a region critical for the structural integrity of the MFS transporter core. Conservation mapping showed that while TMH6 is generally a moderately variable (blue-coded) region, specific residues remain highly conserved (S1 Fig). Strain DUH 10 displayed a V170A substitution (Valine to Alanine) in TMH6, which comparative alignment revealed is a baseline polymorphism shared with UPEC reference strain CFT073 (Accession: AAN83032.1). Notably, strain DUH 02 exhibited an A173T substitution (Alanine to Threonine), representing a significant physicochemical shift from a non-polar to a polar residue and standing as a novel variant absent in commensal K-12, UPEC reference strains, and wider BLAST datasets (Table 3). A recurrent substitution was observed in the twelfth transmembrane helix near the C-terminus of the protein. At position 304, Valine was substituted with Isoleucine (V304I) in both Strain DUH 04 and Strain DUH 10 (S2 Fig). While position 304 is located within a strictly conserved (red-coded) region of the E. coli emrD consensus (S1 Fig), our analysis revealed significant biochemical plasticity at this site across different strains, including bulky aromatic residues like Phenylalanine (F) and Tryptophan (W). Cross-strain alignment demonstrated that Isoleucine at position 304 (V304I), observed in DUH 04 and DUH 10, is conserved across UPEC reference lineages, including strains CFT073 and 536. While position 304 resides within a conserved region of the consensus, the conservative aliphatic nature of V304I reflects neutral evolutionary divergence characteristic of UPEC isolates rather than a novel destabilizing mutation (Table 3).

Table 3. Summary of genomic diversity, evolutionary conservation, and structural impact of emrD mutations in clinical E. coli isolates.

Sample ID Phylogenetic Cluster DNA Mutation (Nucleotide Level) Amino Acid Change (Protein Level) Structural Location UPEC Reference Match Biochemical Shift Conservation (E. coli) Variant Status & Frequency (n = 25)*
DUH 01, 03, 05, 06, 09, 21 Cluster I / III None None N/A Matches K-12, CFT073 & 536 N/A N/A Wild-Type Baseline
DUH 02 Cluster I (Variant) GCT → ACT Ala173Thr (A173T) Transmembrane Helix 6 Unique (No match) Non-polar → Polar Variable (Blue) Novel Clinical Variant (4%)
DUH 10 Cluster II GTT → GCT

GTT → ATT
Val170Ala (V170A)

Val304Ile (V304I)
Transmembrane Helix6 Transmembrane Helix 12 Matches CFT073

Matches CFT073 & 536
Aliphatic → Aliphatic

Aliphatic → Aliphatic
Conserved (Red)

Conserved (Red)
UPEC Lineage Feature (4%) UPEC Baseline Feature (8%)
DUH 04 Cluster II GTT → ATT Val304Ile (V304I) Transmembrane Helix 12 Matches CFT073 & 536 Aliphatic → Aliphatic Conserved (Red) UPEC Baseline Feature (8%)

*Frequencies (n = 25) are calculated relative to a preliminary dataset of 25 E. coli reference sequences retrieved via NCBI BLASTp to provide sequence context rather than global population estimates. Conservation scores are based on NCBI BLASTp multiple sequence alignment (S1 Fig). Reference strain accessions: K-12 MG1655 (NP_416685.1), CFT073 (AAN83032.1), and 536 (WP_001335494.1).

Fig 3. Structural localization of clinical EmrD mutations.

Fig 3

Ribbon representation of the EmrD multidrug efflux pump (based on PDB: 2GFP) generated in PyMOL. The three non-synonymous substitutions identified in this study are highlighted in magenta and labeled with their corresponding single-letter amino acid codes. V170 and A173 are situated within Transmembrane Helix 6 (TMH6), while V304 is located within Transmembrane Helix 12 (TMH12). This illustration shows the positions of these variants within the transporter framework, providing a structural context for future studies.

Strain DUH 10 emerged as a unique variant in this dataset, harboring mutations in two distinct transmembrane domains: V170A in Helix 6 and V304I in Helix 12. This specific mutational profile requires further structural and functional characterization to determine its effects on protein conformation and substrate transport.

Discussion

The rising prevalence of multidrug-resistant (MDR) UPEC in the Kurdistan region necessitates a deeper understanding of the interplay between acquired resistance determinants and intrinsic efflux mechanisms. In this study, we provide a genomic characterization of the emrD multidrug efflux transporter in clinical isolates. Our results demonstrate that while the emrD gene is universally conserved in these MDR strains, it harbors specific non-synonymous mutations within critical transmembrane domains, suggesting localized evolutionary adaptation.

Physiological role: virulence and host-pathogen interaction

The detection of emrD in 100% of the isolates (n = 10) underscores its status as a core housekeeping gene, distinct from the horizontally acquired blaCTX-M genes. Alvarez-Ortega et al. have previously noted that while acquired genes provide high-level resistance, intrinsic pumps like EmrD are evolutionarily ancient and essential for cellular homeostasis [5]. However, the role of EmrD likely extends beyond mere detoxification. Pasqua et al. recently highlighted that MFS pumps act as mediators of “host-pathogen communication” by extruding host-derived antimicrobial signals, such as bile salts, fatty acids, and prostaglandins [22,23]. Furthermore, Fanelli et al. demonstrated that the expression of efflux pumps is critical for E. coli survival within the oxidative and acidic environment of macrophages [24]. However, because emrD is a conserved core gene found in both pathogenic and non-pathogenic E. coli, its universal presence likely reflects genomic conservation rather than a specific role in UPEC virulence or host colonization..

Co-resistance of EmrD variants and β-lactamase genes

The clinical severity of these isolates is highlighted by the co-occurrence of EmrD with blaCTX-M-1 and blaTEM β-lactamases. This aligns with the “crossroad” hypothesis proposed by Alcalde-Rico et al., where efflux pumps and enzymatic resistance mechanisms evolve cooperatively to ensure survival against combined therapies [3]. Such co-selection suggests that EmrD variants are maintained alongside β-lactamase genes in Iraqi UPEC isolates. Previous studies have linked efflux pump regulation with biofilm formation and motility [25]

Phylogenetic diversity and evolutionary dynamics

While efflux pump genes are traditionally viewed as highly conserved elements of the bacterial core genome [4], our phylogenetic analysis reveals unexpected genetic heterogeneity within the emrD sequences. The segregation of isolates into three distinct clusters (I, II, and III) indicates that the emrD gene in this geographical region is not monoclonal but rather associated with diverse E. coli lineages (Fig 2). The predominance of Cluster I (containing 60% of isolates, including isolate DUH 06) suggests the local expansion of a dominant UPEC clone that maintains the wild-type emrD sequence. In contrast, the extensive branch length observed for strain DUH 11 highlights a divergent evolutionary trajectory. This outlier status likely reflects the accumulation of silent mutations or a distinct phylogenetic background (e.g., a different E. coli phylogroup), similar to the chromosomal heterogeneity recently described in UPEC isolates from Uganda by Maghembe et al. (2024) [17]. We emphasize that the blaSHV-positive status of DUH 11 (along with blaCTX-M-1 and blaTEM) is plasmid-borne and uncoupled from its chromosomal sequence divergence. Importantly, comparative sequence alignment revealed that the V304I substitution is conserved in prototypical UPEC reference strains CFT073 and 536, while V170A matches strain CFT073. Without dN/dS analysis or population-scale genomic data, these substitutions reflect neutral lineage-specific polymorphisms within UPEC rather than adaptive evolution under novel selection pressures.

Structural implications of the EmrD mutations

A pivotal finding of this study is the identification of the V170A mutation in Helix 6 (TM6) and the V304I mutation in Helix 12 (TM12) (Fig 3). Crucially, cross-strain comparisons demonstrate that V304I represents a baseline UPEC lineage feature shared with both reference strains CFT073 and 536, while V170A is shared specifically with strain CFT073. In contrast, the A173T substitution in strain DUH 02 represents a novel, unique clinical variant absent from all reference strains. Structural crystallographic studies of EmrD by Yin et al. revealed that the transporter is composed of 12 transmembrane helices surrounding a hydrophobic internal cavity, utilizing a “rocker-switch” mechanism to translocate amphipathic substrates across the inner membrane [13]. This scaffold operates via a ‘rocker-switch’ mechanism, characterized by large-scale alternating access movements between inward-open and outward-open states [26]. Our identification of mutations in TMH6 and TMH12 is significant because these helices are central to this pivoting motion, potentially influencing the speed or efficiency of the switch during substrate export. Ranaweera et al. further established that in the MFS, Helices 6 and 12 frequently line the substrate-translocation pathway and contain residues critical for substrate recognition [14]. We hypothesize that the V170A and V304I substitutions modulate the conformational plasticity of the transporter. Recent work by Kumar et al. describes MFS binding pockets as “promiscuous” and highly flexible, relying on an “induced fit” mechanism to accommodate diverse antibiotics [12]. The localization of mutations V170A, A173T, and V304I within these central helices is highly significant, as structural flexibility in these regions is required for substrate binding and release. While baseline UPEC lineage polymorphisms (V170A and V304I) were present in 4% and 8% of our initial screening BLAST dataset, respectively, the novel A173T variant remains unobserved across global reference datasets, highlighting its unique distribution in clinical isolate DUH 02. However, their evolutionary significance cannot be determined from sequence data alone and requires further functional and population-level investigation. The substitution of Valine with Alanine (V170A) shared with strain CFT073 reduces side-chain volume, which may alter the packing density of Helix 6, potentially modifying the “structural wobble” required for the transporter to capture newer generation fluoroquinolones or cephalosporins. This is consistent with the possibility that EmrD variants may undergo structural diversification under antibiotic selection pressures, although this remains speculative. Furthermore, the shift from bulky aromatic residues (like F304) to smaller aliphatic residues (like I304) in our isolates and UPEC reference strains is hypothesized to alter the internal cavity volume. Notably, the introduction of a polar Threonine at position 173 in the novel DUH 02 variant could theoretically facilitate new hydrogen-bonding interactions within TMH6 during the conformational cycle. Although these substitutions could theoretically influence the induced-fit mechanism described for MFS transporters, their effects on transporter dynamics and substrate recognition remain unknown without molecular dynamics simulations and functional validation. Therefore, the structural and evolutionary significance of the Cluster II and the novel A173T mutation variants remains unresolved and should be regarded as a hypothesis requiring further structural and functional investigation.

Limitations

This study has limitations inherent to its pilot nature. First, the sample size (n = 10) limits the generalization of the specific mutation frequencies to the broader Middle Eastern UPEC population. Second, while we identified non-synonymous amino acid substitutions (the novel A173T variant alongside UPEC lineage features V170A and V304I), this study relied on genomic and structural prediction and did not employ molecular dynamics simulations, RT-qPCR to quantify emrD transcript levels or site-directed mutagenesis to kinetically validate the V170A/V304I variants. Future studies will focus on the functional characterization of the novel A173T mutant to definitively correlate the genotype with altered minimum inhibitory concentrations (MICs). Third, the scope was bounded by clinical operational categorization of UPEC rather than molecular virulence or Multi Locus Sequence Typing (MLST)/phylogroup profiling, and β-lactamase genes were characterized by PCR screen alone. Finally, primer end-trimming restricted analyzed sequence coverage to residues 32–345, leaving potential variation in the first 31 N-terminal and last 50 C-terminal amino acids unevaluated.

Conclusion

In conclusion, this study confirms that emrD is a highly conserved yet genetically diverse transporter in clinical UPEC isolates. The identification of a novel structural mutation in TMH6 (A173T in strain DUH 02), alongside baseline UPEC lineage polymorphisms (V170A and V304I), supports a model of “induced fit” evolution in MFS transporters, wherein localized structural variations optimize transport dynamics without compromising overall scaffold stability. While functional assays are required for confirmation, these structural alterations are predicted to potentially influence the pump’s conformational dynamics. These findings, coupled with the presence of ESBL genes, suggest that emrD sequence variation represents an active component of the UPEC genomic repertoire, with the potential to play a role in antibiotic tolerance or environmental survival through these observed structural variations.

Supporting information

S1 Fig. Multiple sequence alignment of EmrD from 25 representative Escherichia coli reference strains.

This alignment was performed using BLASTp to assess the evolutionary conservation of residues at positions 170, 173, and 304. Amino acid conservation is indicated by color coding: red denotes strictly conserved residues, while blue indicates regions of moderate to high variability. The alignment illustrates the rarity of the A173T and V304I substitutions identified in the clinical isolates of the current study.

(RTF)

pone.0362259.s001.rtf (74.4KB, rtf)
S1 File. Original, uncropped agarose gel electrophoresis image for PCR amplification products.

(PNG)

pone.0362259.s002.png (507.7KB, png)
S2 Fig. Multiple sequence alignment: The amino acid sequences of ten clinical E. coli isolates (DUH 01 to DUH 21) are aligned against the E. coli K-12 reference sequence (EmrD_Ref) and two prototypical uropathogenic E. coli (UPEC) reference strains: CFT073 (Accession: AAN83032.1) and 536 (Accession: WP_001335494.1).

Asterisks (*) indicate positions with fully conserved residues; colons (:) indicate conservation between groups of strongly similar properties; and periods (.) indicate conservation between groups of weakly similar properties. Non-synonymous substitutions are highlighted by a lack of an asterisk at the corresponding position: the novel A173T in strain DUH 02 (TMH6), alongside baseline UPEC lineage-conserved features V170A in strain DUH 10 (TMH6; shared with strain CFT073)), and V304I in strains DUH 04 and DUH 10 (TMH12; shared with strains CFT073 and 536). Note: Terminal primer end-trimming restricted the analyzed clinical sequence range to residues 32–345, leaving The initial 31 amino acids for clinical isolates un-evaluated, while the core transmembrane machinery remains intact and fully aligned.

(PDF)

pone.0362259.s003.pdf (41.7KB, pdf)

Acknowledgments

The authors would like to thank the University of Duhok for providing the laboratory facilities and support required to conduct this research.

Declaration of Generative AI and AI-assisted technologies in the writing process During the preparation of this work, the authors used Gemini (Google) for English language editing, proofreading, and grammatical refinement. Following the use of this tool, the authors reviewed and edited the content as needed and took full responsibility for the content of the publication.

Data Availability

All nucleotide sequences generated for the emrD gene in this study have been deposited in the NCBI GenBank database (https://www.ncbi.nlm.nih.gov/genbank/) and are fully public. They can be accessed using the accession numbers PZ196343 through PZ196352.

Funding Statement

The author(s) received no specific funding for this work.

References

  • 1.Amaral L, Martins A, Spengler G, Molnar J. Efflux pumps of Gram-negative bacteria: what they do, how they do it, with what and how to deal with them. Front Pharmacol. 2014;4:168. doi: 10.3389/fphar.2013.00168 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Li X-Z, Nikaido H. Efflux-mediated drug resistance in bacteria: an update. Drugs. 2009;69(12):1555–623. doi: 10.2165/11317030-000000000-00000 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Alcalde-Rico M, Hernando-Amado S, Blanco P, Martínez JL. Multidrug efflux pumps at the crossroad between antibiotic resistance and bacterial virulence. Front Microbiol. 2016;7:1483. doi: 10.3389/fmicb.2016.01483 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Piddock LJV. Multidrug-resistance efflux pumps - not just for resistance. Nat Rev Microbiol. 2006;4(8):629–36. doi: 10.1038/nrmicro1464 [DOI] [PubMed] [Google Scholar]
  • 5.Alvarez-Ortega C, Olivares J, Martínez JL. RND multidrug efflux pumps: what are they good for? Front Microbiol. 2013;4. doi: 10.3389/fmicb.2013.00007 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Du D, Wang-Kan X, Neuberger A, van Veen HW, Pos KM, Piddock LJV, et al. Multidrug efflux pumps: structure, function and regulation. Nat Rev Microbiol. 2018;16(9):523–39. doi: 10.1038/s41579-018-0048-6 [DOI] [PubMed] [Google Scholar]
  • 7.Delmar JA, Yu EW. The AbgT family: A novel class of antimetabolite transporters. Protein Sci. 2016;25(2):322–37. doi: 10.1002/pro.2820 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Pao SS, Paulsen IT, Saier MH. Major facilitator superfamily. Microbiol Mol Biol Rev. 1998;62:1–34. doi: 10.1128/MMBR.62.1.1-34.1998 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Pasqua M, Grossi M, Zennaro A, Fanelli G, Micheli G, Barras F, et al. The varied role of efflux pumps of the mfs family in the interplay of bacteria with animal and plant cells. Microorganisms. 2019;7(9):285. doi: 10.3390/microorganisms7090285 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Nishino K, Yamasaki S, Nakashima R, Zwama M, Hayashi-Nishino M. Function and inhibitory mechanisms of multidrug efflux pumps. Front Microbiol. 2021;12:737288. doi: 10.3389/fmicb.2021.737288 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Yan N. Structural advances for the major facilitator superfamily (MFS) transporters. Trends Biochem Sci. 2013;38(3):151–9. doi: 10.1016/j.tibs.2013.01.003 [DOI] [PubMed] [Google Scholar]
  • 12.Kumar S, Lekshmi M, Parvathi A, Ojha M, Wenzel N, Varela MF. Functional and structural roles of the major facilitator superfamily bacterial multidrug efflux pumps. Microorganisms. 2020;8(2):266. doi: 10.3390/microorganisms8020266 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Yin Y, He X, Szewczyk P, Nguyen T, Chang G. Structure of the multidrug transporter EmrD from Escherichia coli. Science. 2006;312(5774):741–4. doi: 10.1126/science.1125629 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Ranaweera I, Shrestha U, Ranjana KC, Kakarla P, Willmon TM, Hernandez AJ, et al. Structural comparison of bacterial multidrug efflux pumps of the major facilitator superfamily. Trends Cell Mol Biol. 2015;10:131–40. [PMC free article] [PubMed] [Google Scholar]
  • 15.Yousefian N, Ornik-Cha A, Poussard S, Decossas M, Berbon M, Daury L, et al. Structural characterization of the EmrAB-TolC efflux complex from E. coli. Biochim Biophys Acta Biomembr. 2021;1863(1):183488. doi: 10.1016/j.bbamem.2020.183488 [DOI] [PubMed] [Google Scholar]
  • 16.Whelan S, Lucey B, Finn K. Uropathogenic Escherichia coli (UPEC)-associated urinary tract infections: the molecular basis for challenges to effective treatment. Microorganisms. 2023;11(9):2169. doi: 10.3390/microorganisms11092169 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Maghembe RS, Magulye MAK, Eilu E, Sekyanzi S, Mwesigwa S, Katagirya E. Chromosomal and plasmid-encoded virulence and multidrug resistance of Escherichia coli ST58/24 infecting a 2-year-old sickle cell patient with sepsis in Kampala Uganda, East Africa. Heliyon. 2024;10(9):e30187. doi: 10.1016/j.heliyon.2024.e30187 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Alnaqshabandy I. Molecular characterization of Escherichia coli isolated from UTI patients attending Azadi Hospital in Duhok City. University of Zakho. 2012. [Google Scholar]
  • 19.Han Y, Zhang Y, Zhang X, Huang Z, Kong J, Wang X, et al. PAM-1: an antimicrobial peptide with promise against ceftazidime-avibactam resistant Escherichia coli infection. Front Microbiol. 2024;15:1291876. doi: 10.3389/fmicb.2024.1291876 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Madeira F, Madhusoodanan N, Lee J, Eusebi A, Niewielska A, Tivey ARN, et al. The EMBL-EBI Job Dispatcher sequence analysis tools framework in 2024. Nucleic Acids Res. 2024;52(W1):W521–5. doi: 10.1093/nar/gkae241 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Nei M, Kumar S. Molecular evolution and phylogenetics. New York: Oxford University Press. 2000. [Google Scholar]
  • 22.Pasqua M, Bonaccorsi di Patti MC, Fanelli G, Utsumi R, Eguchi Y, Trirocco R, et al. Host - Bacterial pathogen communication: the wily role of the multidrug efflux pumps of the MFS Family. Front Mol Biosci. 2021;8:723274. doi: 10.3389/fmolb.2021.723274 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Alav I, Kobylka J, Kuth MS, Pos KM, Picard M, Blair JMA, et al. Structure, assembly, and function of Tripartite Efflux and type 1 secretion systems in gram-negative bacteria. Chem Rev. 2021;121(9):5479–596. doi: 10.1021/acs.chemrev.1c00055 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Fanelli G, Pasqua M, Colonna B, Prosseda G, Grossi M. Expression profile of multidrug resistance efflux pumps during intracellular life of adherent-invasive Escherichia coli strain LF82. Front Microbiol. 2020;11:1935. doi: 10.3389/fmicb.2020.01935 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Yan J, Li Y, Guo X, Wang X, Liu F, Li A, et al. The effect of ArcA on the growth, motility, biofilm formation, and virulence of Plesiomonas shigelloides. BMC Microbiol. 2021;21(1):266. doi: 10.1186/s12866-021-02322-y [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Sauve S, Williamson J, Polasa A, Moradi M. Ins and outs of rocker switch mechanism in major facilitator superfamily of transporters. Membranes (Basel). 2023;13(5):462. doi: 10.3390/membranes13050462 [DOI] [PMC free article] [PubMed] [Google Scholar]

Decision Letter 0

Daniel F M Monte

2 Jun 2026

Dear Dr. Alnaqshabandy,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by Jul 17 2026 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

  • A letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

As the corresponding author, your ORCID iD is verified in the submission system and will appear in the published article. PLOS supports the use of ORCID, and we encourage all coauthors to register for an ORCID iD and use it as well. Please encourage your coauthors to verify their ORCID iD within the submission system before final acceptance, as unverified ORCID iDs will not appear in the published article. Only  the individual author can complete the verification step; PLOS staff cannot  verify ORCID iDs on behalf of authors.

We look forward to receiving your revised manuscript.

Kind regards,

Daniel F. M. Monte, Ph.D.

Academic Editor

PLOS One

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. Please note that your Data Availability Statement is currently missing the accession number of each dataset can’t access. If your manuscript is accepted for publication, you will be asked to provide these details on a very short timeline. We therefore suggest that you provide this information now, though we will not hold up the peer review process if you are unable.

3. PLOS ONE now requires that authors provide the original uncropped and unadjusted images underlying all blot or gel results reported in a submission’s figures or Supporting Information files. This policy and the journal’s other requirements for blot/gel reporting and figure preparation are described in detail at https://journals.plos.org/plosone/s/figures#loc-blot-and-gel-reporting-requirements and https://journals.plos.org/plosone/s/figures#loc-preparing-figures-from-image-files. When you submit your revised manuscript, please ensure that your figures adhere fully to these guidelines and provide the original underlying images for all blot or gel data reported in your submission. See the following link for instructions on providing the original image data: https://journals.plos.org/plosone/s/figures#loc-original-images-for-blots-and-gels.

In your cover letter, please note whether your blot/gel image data are in Supporting Information or posted at a public data repository, provide the repository URL if relevant, and provide specific details as to which raw blot/gel images, if any, are not available. Email us at plosone@plos.org if you have any questions.

4. If the reviewer comments include a recommendation to cite specific previously published works, please review and evaluate these publications to determine whether they are relevant and should be cited. There is no requirement to cite these works unless the editor has indicated otherwise.

Additional Editor Comments:

Thank you for submitting your manuscript. The reviewer acknowledges the relevance of the topic and the value of investigating the molecular diversity of the emrD efflux transporter in MDR UPEC isolates. The integration of sequence analysis, phylogenetic assessment, and structural mapping is a strength of the study, and the data provide useful descriptive information from an underrepresented geographic region.

However, substantial revisions are required. The main concern is that several conclusions extend beyond the evidence presented. While the study identifies emrD variants and maps them to structurally relevant regions, no functional experiments were performed to demonstrate effects on efflux activity, antimicrobial resistance, substrate specificity, virulence, or adaptation. Therefore, interpretations suggesting adaptive evolution, altered transporter function, or direct contributions to multidrug resistance should be significantly moderated and presented as hypotheses rather than conclusions.

The discussion should more clearly distinguish between observations supported by the data and speculative interpretations. In addition, the limitations of the study—including the small sample size, lack of susceptible comparator strains, limited phylogenetic context, and absence of functional validation—should be more explicitly acknowledged. The phylogenetic and evolutionary interpretations should also be revised to avoid unsupported inferences regarding selection, adaptation, or dissemination.

Overall, the manuscript has merit as an exploratory and hypothesis-generating study, but its conclusions require substantial revision to align with the data presented. The authors should carefully address all reviewer comments and provide a detailed point-by-point response in the revised submission.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

Reviewer #1: Partly

Reviewer #2: Yes

**********

2. Has the statistical analysis been performed appropriately and rigorously? -->?>

Reviewer #1: N/A

Reviewer #2: Yes

**********

3. Have the authors made all data underlying the findings in their manuscript fully available??>

The PLOS Data policy

Reviewer #1: Yes

Reviewer #2: No

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English??>

Reviewer #1: Yes

Reviewer #2: Yes

**********

Reviewer #1: The manuscript presents a relevant and potentially interesting proposal by investigating the molecular diversity of the EmrD efflux transporter in clinical MDR UPEC isolates, particularly through the integration of phylogenetic analysis, mutation identification, and structural contextualisation. The overall rationale is coherent and well aligned with the current antimicrobial resistance landscape in uropathogenic Escherichia coli. The Introduction adequately contextualises efflux systems within the MFS superfamily and appropriately positions EmrD as a comparatively underexplored component relative to more extensively studied systems such as AcrAB-TolC. Moreover, the study is logically organised, and the integration of molecular and structural analyses constitutes the strongest aspect of the work.

Despite these strengths, the manuscript suffers from a recurring and substantial issue: it consistently extrapolates beyond what the data actually demonstrate. In several instances, the text transforms plausible hypotheses into near-assertive interpretations, particularly when suggesting that mutations within TMH6 and TMH12 may alter transport efficiency, conformational plasticity, adaptation to clinical environments, or even contribute directly to multidrug resistance. The study demonstrates only the universal presence of emrD, the existence of sequence variation, and the structural localisation of these substitutions within relevant transmembrane regions. No functional experiments were conducted to demonstrate altered efflux activity, changes in substrate specificity, differences in MIC values, altered gene expression, or any phenotypic consequence associated with the identified variants.

This limitation is particularly important because the manuscript implicitly constructs a mechanistic chain in which structural mutations would lead to conformational changes, subsequently modifying substrate export efficiency and ultimately contributing to adaptation under antibiotic pressure. None of these intermediate steps are experimentally validated. As a result, the text frequently implies causality where only observational correlation exists. This concern is amplified by the fact that emrD is a chromosomal core gene broadly distributed across E. coli, including fully susceptible strains. Consequently, the mere presence of emrD in MDR isolates does not support conclusions regarding its functional contribution to the resistance phenotype.

Another major concern relates to the evolutionary interpretation of the identified mutations. The manuscript repeatedly describes rare variants as “specialised adaptations” or evidence of “structural fine-tuning under antibiotic pressure”, yet no robust evolutionary analyses were performed to support such claims. There is no assessment of positive selection, dN/dS ratios, codon-level evolutionary pressure, population structure, or broader phylogenetic context using large-scale genomic datasets. The rarity of a mutation does not, in itself, imply adaptive significance. The observed substitutions may simply reflect neutral drift, lineage-specific polymorphism, chromosomal background variation, or stochastic diversification within local UPEC populations.

The structural discussion is conceptually interesting, particularly in linking TMH6 and TMH12 to the “rocker-switch” mechanism characteristic of MFS transporters. Nevertheless, the manuscript repeatedly exceeds the interpretative limits permitted by positional structural mapping alone. For example, the V304I substitution is biochemically highly conservative, involving hydrophobic branched-chain residues with similar physicochemical properties. Even the A173T mutation, although potentially more relevant due to its polar shift, remains entirely hypothetical in functional terms. The manuscript repeatedly infers altered conformational flexibility, modified cavity architecture, or altered substrate recognition despite the absence of molecular dynamics simulations, docking analyses, stability calculations, or any direct structural modelling beyond residue localisation.

The phylogenetic analysis also requires more cautious interpretation. The study includes only ten clinical isolates and a highly limited comparative dataset. The identified clustering patterns are likely to reflect broader clonal relationships among bacterial lineages rather than adaptive selection acting specifically upon emrD. Without genome-wide phylogenetic context, it is impossible to distinguish gene-specific adaptation from simple chromosomal inheritance. Furthermore, the extremely small sample size severely limits any meaningful inference regarding mutation frequency, evolutionary dynamics, or regional dissemination patterns.

From a methodological standpoint, the work is acceptable as an exploratory pilot study but falls considerably short of the current state-of-the-art required to support mechanistic conclusions. The absence of susceptible control strains is a major limitation, as it prevents any assessment of whether the identified variants are enriched among MDR isolates. Similarly, no expression analyses were performed, such as RT-qPCR, which could at least have addressed whether regulatory differences accompany the coding sequence variation. Functional assays such as ethidium bromide accumulation, efflux inhibition assays, MIC comparisons, site-directed mutagenesis, or complementation experiments would be essential to validate the proposed functional implications of the mutations identified.

The Discussion section is arguably the most problematic component of the manuscript. Although generally well written and supported by relevant literature on MFS transporters, it repeatedly inflates the biological implications of the findings. The text attributes potential roles to EmrD in virulence, intracellular survival, host adaptation, and biofilm formation, despite none of these features having been experimentally investigated in this study. Moreover, the cited literature often concerns MFS efflux systems broadly rather than EmrD specifically in the analysed strains. The manuscript therefore transfers general properties of the superfamily directly onto the specific variants identified here, which is not sufficiently justified.

In terms of novelty, the study possesses moderate merit as a regional exploratory survey. The identification and structural contextualisation of emrD variants in Iraqi MDR UPEC isolates may hold descriptive and epidemiological value, particularly given the relative underrepresentation of such populations in the literature. However, the majority of the work remains fundamentally descriptive. The principal contribution lies in variant detection and structural localisation rather than the demonstration of novel resistance mechanisms. Consequently, the manuscript is more appropriately framed as a preliminary molecular diversity study than as evidence for adaptive structural evolution of EmrD associated with multidrug resistance.

The figures are broadly coherent with the manuscript text but present several limitations. Figure 1 suffers from poor visual quality and insufficient contrast. Figure 2 has limited resolution and poorly interpretable bootstrap support, whilst Figure 3, although conceptually the strongest, represents only positional mapping rather than rigorous structural analysis. The figure legends generally correspond well to the manuscript; however, in some cases they reinforce mechanistic interpretations that are not adequately supported by the data.

Overall, the manuscript contains potentially useful observations and an interesting attempt to integrate genetic diversity with structural protein analysis. Nevertheless, the conclusions require substantial moderation. The study should be reframed as an exploratory and hypothesis-generating analysis rather than as evidence of functional adaptive evolution linked to multidrug resistance. The primary revision required is a clearer distinction between what has actually been demonstrated and what remains speculative. Without additional functional validation, statements relating to altered efflux efficiency, adaptation under antibiotic pressure, virulence contribution, or structural specialisation should be reformulated using considerably more cautious and hypothetical language.

Reviewer #2: General Comments and Analysis: This manuscript provides an interesting genomic and structural characterization of the emrD efflux pump in multidrug-resistant (MDR) Uropathogenic Escherichia coli (UPEC) isolates from the Kurdistan region. The study is highly relevant as it bridges the gap between traditional molecular epidemiology (detection of bla genes) and structural bioinformatics. By identifying specific mutations in the transmembrane helices (TMH6 and TMH12) and correlating them with phylogenetic lineages, the authors offer a sophisticated view of bacterial adaptation. The use of protein modeling (PDB: 2GFP) to hypothesize on the "induced fit" mechanism adds significant value. However, several technical inconsistencies, nomenclature issues, and formatting errors must be addressed to meet the standard for international publication.

Specific Suggestions and Comments

Title and Affiliations

Affiliation Mapping: Please clarify why the affiliations are indicated with two different numbers if they refer to the same institution. This should be consolidated to avoid confusion.

Introduction and Background

Line 68: “membrane [15,16]”. Ensure there is a space before the brackets, if required by the journal style.

Line 73: Extra letters “Uropathogenic”.

Line 74: Grammar correction: Change to "...responsible for 75% of uncomplicated..." to ensure clarity.

Line 103: Regarding the mention of cloxacillin: It is important to note that E. coli is inherently resistant to cloxacillin. Reporting this as an "acquired resistance" or a significant finding might be seen as a lack of microbiological context.

Materials and Methods

Line 114 (Primer Concentration): There is a potential discrepancy in the reaction volume. You mention using 2 µL of a 5 µM stock, which results in 10 pmol per reaction. Please verify if the intended amount was 5 pmol (absolute amount) or if the stock concentration was different.

Line 119 (Table 1 & References): * It is highly recommended to merge the primer data into a single, cohesive table. Currently, blaNDM appears twice (positions 1 and 6).

Reference [21] must be cited in the main text. Example: "The primers used for β-lactamase gene detection were obtained from previous studies [21] and are summarized in Table 1."

Line 135: Specify the exact strain of E. coli K-12 used (e.g., MG1655, W3110).

Line 136: Define the acronym upon first use: MAFFT (Multiple Alignment using Fast Fourier Transform).

Line 139: Accession Numbers: I was unable to locate the mentioned accession numbers in the NCBI database. These must be public and searchable before publication.

Line 151 (Reference Sequences): Please provide a rationale for selecting exactly 25 reference sequences. Were these selected to represent different phylogroups, or were they simply the top 25 hits from a BLAST search?

Line 152 (Table Numbering): Table 3 is cited before Table 2. Tables must be numbered sequentially according to their appearance in the text.

Results

Line 156: Suggested phrasing: "...exhibited a uniform multidrug-resistant (MDR) …"

Line 157: Mentioning "100% resistance" to cloxacillin is technically accurate but clinically irrelevant for E. coli. I suggest removing or de-emphasizing this.

Line 165 (PCR Product Size): In Table 1, the expected size is 1,076 bp. However, the text mentions approximately 1,200 bp. This discrepancy (over 100 bp) needs to be explained or corrected to ensure the integrity of the PCR results.

Line 200 (Character Rendering): The symbol “ ” (Beta) appears as a “Ghost Character” in my PDF reader. Please check if this is a rendering error or if there is actually a problem.

Line 204 (Strain Nomenclature): Standardize the strain IDs throughout the manuscript. The text alternates between space and hyphen (e.g., "DUH 04" vs. "DUH-04").

Line 205 (Phylogeny): There is a contradiction regarding the "basal" strain. Earlier, DUH 11 was identified as the divergent/basal outlier, but here DUH 01 is mentioned.

References

Line 341 (Zotero/Citations): Before submission, ensure you "Unlink Citations" if using Zotero. Also, standardize journal names: either use full names or standard ISO abbreviations consistently for all entries.

Line 354: There is a repeated title in section 7. Please remove the duplication.

Line 389 (Reference 21): Please verify this source. Reference [21] is cited for the primers, but it does not appear to be the original source/designer of these sequences. It is better to cite the original methodology papers.

**********

what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review?  For information about this choice, including consent withdrawal, please see our Privacy Policy

Reviewer #1: No

Reviewer #2: Yes:  Alan Douglas de Lima Rocha

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

To ensure your figures meet our technical requirements, please review our figure guidelines: https://journals.plos.org/plosone/s/figures

You may also use PLOS’s free figure tool, NAAS, to help you prepare publication quality figures: https://journals.plos.org/plosone/s/figures#loc-tools-for-figure-preparation.

NAAS will assess whether your figures meet our technical requirements by comparing each figure against our figure specifications.

PLoS One. 2026 Nov 11;21(11):e0362259. doi: 10.1371/journal.pone.0362259.r002

Author response to Decision Letter 1


29 Jul 2026

Dear Academic Editor Dr. Daniel F. M. Monte and Reviewers,

Thank you very much for your highly constructive and encouraging feedback on our manuscript (PONE-D-26-16505). We have taken all comments into serious consideration and have thoroughly revised our manuscript to address every point raised.

Due to the length and detailed formatting of our point-by-point responses (including line-number references and blockquotes), we have uploaded our complete, detailed "Response to Reviewers" as a separate document.

Below is a brief summary of the key revisions we have implemented:

Moderated Interpretative Claims (Editor & Reviewer 1): We have significantly moderated our evolutionary and structural conclusions—shifting them from definitive claims to exploratory hypotheses—to accurately reflect the pilot nature of this survey.

Dedicated Study Limitations (Editor & Reviewer 1): We have added a dedicated "Study Limitations" section explicitly addressing the pilot nature of the study, the small sample size (n=10), and the lack of molecular dynamics simulations, RT-qPCR transcript quantification, or site-directed mutagenesis to kinetically validate the V170A/V304I variants.

Correction of Nomenclature & Technical Formatting (Reviewer 2): We have meticulously addressed all technical points raised by Reviewer 2 across the manuscript's 19 comments. This includes standardizing our strain naming convention (e.g., using "DUH 04" consistently), correcting the phylogenetic branch descriptions (clarifying the basal position of DUH 11), resolving font-rendering issues for the symbol "β", adjusting PCR primer/volume calculations, and unlinking Zotero citation metadata.

Data Availability & Integrity (Editor & Reviewer 2): All 10 generated nucleotide sequences are now fully public and searchable in the NCBI GenBank database (accession numbers PZ196343 through PZ196352). Additionally, we have provided original, uncropped gel images under "S1_Raw_Images".

We hope these extensive revisions and clarifications make our manuscript fully suitable for publication in PLOS ONE.

Please refer to our uploaded "Response to Reviewers" file for the complete, word-for-word responses to every individual comment.

Sincerely,

Dr. Iman H. F. Alnaqshabandy

University of Duhok

Attachment

Submitted filename: Response to Reviewers.docx

pone.0362259.s005.docx (23.6KB, docx)

Decision Letter 1

Daniel F M Monte

19 Aug 2026

Dear Dr. Alnaqshabandy,

Thank you for submitting your manuscript to PLOS One. After careful consideration, we feel that it has merit but does not fully meet PLOS One’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by Oct 03 2026 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

  • A letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS One offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

As the corresponding author, your ORCID iD is verified in the submission system and will appear in the published article. PLOS supports the use of ORCID, and we encourage all coauthors to register for an ORCID iD and use it as well. Please encourage your coauthors to verify their ORCID iD within the submission system before final acceptance, as unverified ORCID iDs will not appear in the published article. Only  the individual author can complete the verification step; PLOS staff cannot  verify ORCID iDs on behalf of authors.

We look forward to receiving your revised manuscript.

Kind regards,

Daniel F. M. Monte, Ph.D.

Academic Editor

PLOS One

Journal Requirements:

If the reviewer comments include a recommendation to cite specific previously published works, please review and evaluate these publications to determine whether they are relevant and should be cited. There is no requirement to cite these works unless the editor has indicated otherwise.

Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice.

Additional Editor Comments:

Please, address the comments point-by-point.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

Reviewer #1: (No Response)

Reviewer #2: All comments have been addressed

**********

2. Is the manuscript technically sound, and do the data support the conclusions??>

Reviewer #1: Partly

Reviewer #2: Yes

**********

3. Has the statistical analysis been performed appropriately and rigorously? -->?>

Reviewer #1: N/A

Reviewer #2: Yes

**********

4. Have the authors made all data underlying the findings in their manuscript fully available??>

The PLOS Data policy

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English??>

Reviewer #1: Yes

Reviewer #2: Yes

**********

Reviewer #1: The manuscript presents a coherent and well-organized pilot study integrating molecular detection, sequencing, phylogenetic analysis, and structural mapping to characterize genomic diversity in the emrD efflux pump among ten clinical MDR UPEC isolates. Following the previous round of revision, the interpretive tone has been substantially improved, with speculative and mechanistic language now more consistently distinguished from observation, and the newly added Limitations section appropriately acknowledges the pilot nature of the study and the absence of functional validation. Despite these improvements, several methodological and conceptual issues remain that constrain how confidently the reported findings can be interpreted.

The most significant concern relates to the reference sequence used for variant calling. Escherichia coli K-12 MG1655 is a well-established comparator in UPEC genomics for whole-genome comparisons or virulence-related phenotypic assays, where it serves as the species' neutral genomic backbone, but the present analysis is considerably narrower in scope, calling single-nucleotide and amino-acid substitutions within one core gene using K-12 as the sole point of comparison. Because K-12 belongs to phylogroup A while UPEC isolates typically belong to phylogroups B2 or D, some or all of the substitutions identified may reflect general clonal divergence between phylogroups rather than a variant that emerged locally within these isolates. The authors appear to recognize this ambiguity themselves in the Results, noting that it is unclear whether the observed variation reflects pressures acting specifically on emrD or simply differences in broader clonal background, yet this uncertainty is never resolved methodologically. Including the emrD sequence of at least one published, prototypical UPEC genome, such as CFT073 or 536, alongside K-12 in the comparative alignment would allow the authors to distinguish substitutions shared with a UPEC reference but absent from K-12, which would more plausibly reflect UPEC-associated divergence, from substitutions unique to individual isolates and absent from both references, which would be more consistent with local lineage drift. This addition requires no new laboratory work and would meaningfully strengthen the evolutionary argument the Discussion is attempting to build.

A related concern applies to the set of 25 reference sequences used to calculate how rare or common each substitution is. Because these were selected as the top BLASTp hits by identity and coverage, the resulting set is likely to be highly similar both to the query and to one another, which is not equivalent to a representative sample of global E. coli diversity. Since the claims of rarity for the A173T and V304I substitutions rest directly on this reference set, a more phylogenetically stratified sampling approach could yield meaningfully different frequencies, and this should either be justified explicitly or repeated with a more diverse comparator set.

Several smaller methodological gaps compound these concerns. No positive or negative PCR controls are reported for any of the assays, which is particularly relevant given that the beta-lactamase genes were identified by PCR alone and never sequenced. The manuscript speculates that the divergent isolate DUH 11 may belong to a distinct E. coli phylogroup, but no phylotyping or MLST was performed to test this directly, leaving the claim untestable with the data presented. Similarly, all isolates are described as UPEC throughout the manuscript based solely on their clinical source, without confirmation by any UPEC-associated virulence markers, which technically makes them E. coli isolates associated with urinary tract infection rather than confirmed UPEC in the pathotype sense. Finally, the S2 figure legend notes that roughly the first 31 amino acids of each clinical isolate were not sequenced, meaning that variation in this region could not have been detected in any isolate; this gap is directly relevant to the study's central claim of having characterized emrD diversity and should be carried into the Limitations section rather than left in a figure legend alone.

On the conceptual side, the subsection addressing co-resistance and biofilm potential does not present any biofilm data, and the paragraph closes by citing general literature on the association between efflux regulation and biofilm formation without connecting it back to the study's own findings; this reads as an unfinished thought that likely needs either a clearer framing as background context or removal of the biofilm framing altogether. Elsewhere, the manuscript places DUH 11's blaSHV-positive status next to its description as the most phylogenetically divergent isolate without establishing any mechanistic or statistical link between the two, which risks implying a connection to the reader that the data do not actually support.

Reviewer #2: Thank you for thoroughly addressing all questions and making the necessary corrections to the manuscript. The revisions are clear, and I have no further concerns regarding research or publication ethics.

**********

what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review?  For information about this choice, including consent withdrawal, please see our Privacy Policy

Reviewer #1: No

Reviewer #2: Yes:  Alan Douglas de Lima Rocha

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

To ensure your figures meet our technical requirements, please review our figure guidelines: https://journals.plos.org/plosone/s/figures

You may also use PLOS’s free figure tool, NAAS, to help you prepare publication quality figures: https://journals.plos.org/plosone/s/figures#loc-tools-for-figure-preparation.

NAAS will assess whether your figures meet our technical requirements by comparing each figure against our figure specifications.

PLoS One. 2026 Nov 11;21(11):e0362259. doi: 10.1371/journal.pone.0362259.r004

Author response to Decision Letter 2


11 Sep 2026

Dear Academic Editor (Dr. Daniel F. M. Monte) and Reviewer #1,Thank you for your constructive guidance during this second round of review. We have addressed every comment raised by Reviewer #1. A complete, formatted 'Response to Reviewers' PDF has also been uploaded separately to the submission system.Below is our point-by-point response:Responses to Reviewer #1

Comment 1: Choice of Comparator Sequence (K-12 vs. Prototypical UPEC References)Response: We thank the reviewer for this insightful critique. We expanded our comparative alignment by retrieving and incorporating full-length emrD sequences from two prototypical UPEC reference strains—CFT073 (NCBI Accession: AAN83032.1) and 536 (NCBI Accession: WP_001335494.1)—alongside K-12 MG1655 across our 10 clinical isolates. This dual-comparator approach allowed us to methodologically categorize substitutions into baseline UPEC lineage-conserved features (V170A and V304I) and novel, isolate-specific variants (A173T in isolate DUH 02). We updated the Materials and methods, Results, Discussion, Limitations, and Conclusion sections, as well as Table 2 and the S2 figure legend, to reflect this expanded dataset.

Comment 2: Diversity of the 25 BLAST SequencesResponse: We updated our primary sequence processing workflow to directly include CFT073 and 536 as alignment controls. We also clarified in the In Silico conservation and frequency analysis subsection that the 25 BLASTp sequences represent a curated, non-redundant global panel used specifically to calculate substitution frequencies across diverse pathotypes and geographic origins without overcrowding the core alignment.

Comment 3: Methodological Reporting Gaps (PCR Controls, UPEC Definition, MLST, and Sequence Coverage)Response: We addressed all four reporting details:PCR Controls: Explicitly stated that negative non-template controls (NTC; nuclease-free water) were routinely included in every PCR batch to rule out contamination.UPEC Definition: Clarified that isolates were operationally defined using clinical diagnostic criteria (105 CFU/mL pure culture from symptomatic UTI patients).Phylotyping/MLST: Refined the framing of isolate DUH 11 to avoid speculative claims about specific sequence types or phylogroups without MLST data.Sequence Coverage: Updated sequence descriptions and the Limitations section to explicitly report the analyzed coverage range (residues 32–345), noting that N-terminal (~31 aa) and C-terminal (~50 aa) primer quality trimming left terminal ends uncharacterized.

Comment 4: Conceptual Framing & Biofilm/ESBL UncouplingResponse: We updated the subsection title to "Co-occurrence of EmrD variants and beta-lactamase genes" to ensure it accurately reflects our findings without implying empirical biofilm testing. Additionally, we explicitly clarified in the Discussion that the plasmid-borne ESBL profile of isolate DUH 11 is uncoupled from its chromosomal emrD sequence divergence.

Attachment

Submitted filename: Response_to_Reviewers_auresp_2.docx

pone.0362259.s006.docx (19.9KB, docx)

Decision Letter 2

Daniel F M Monte

22 Oct 2026

Molecular diversity and structural profiling of the EmrD efflux pump in multidrug-resistant uropathogenic Escherichia coli.

PONE-D-26-16505R2

Dear Dr. Alnaqshabandy,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice will be generated when your article is formally accepted. Please note, if your institution has a publishing partnership with PLOS and your article meets the relevant criteria, all or part of your publication costs will be covered. Please make sure your user information is up-to-date by logging into Editorial Manager at Editorial Manager® and clicking the ‘Update My Information' link at the top of the page. For questions related to billing, please contact billing support.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Daniel F. M. Monte, Ph.D.

Academic Editor

PLOS One

Additional Editor Comments (optional):

The comments have been addressed and the reviewers are satisfied.

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

Reviewer #1: All comments have been addressed

Reviewer #2: All comments have been addressed

**********

2. Is the manuscript technically sound, and do the data support the conclusions??>

Reviewer #1: Yes

Reviewer #2: Yes

**********

3. Has the statistical analysis been performed appropriately and rigorously? -->?>

Reviewer #1: N/A

Reviewer #2: Yes

**********

4. Have the authors made all data underlying the findings in their manuscript fully available??>

The PLOS Data policy

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English??>

Reviewer #1: Yes

Reviewer #2: Yes

**********

Reviewer #1: Thank you for addressing my previous comments. The revisions have adequately addressed my concerns, and I have no further major comments.

Reviewer #2: The revisions are clear and satisfactory. I have no further concerns regarding research or publication ethics.

**********

what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review?  For information about this choice, including consent withdrawal, please see our Privacy Policy

Reviewer #1: No

Reviewer #2: Yes:  ALAN DOUGLAS DE LIMA ROCHA

**********

Acceptance letter

Daniel F M Monte

PONE-D-26-16505R2

PLOS One

Dear Dr. Alnaqshabandy,

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS One. Congratulations! Your manuscript is now being handed over to our production team.

At this stage, our production department will prepare your paper for publication. This includes ensuring the following:

* All references, tables, and figures are properly cited

* All relevant supporting information is included in the manuscript submission,

* There are no issues that prevent the paper from being properly typeset

You will receive further instructions from the production team, including instructions on how to review your proof when it is ready. Please keep in mind that we are working through a large volume of accepted articles, so please give us a few days to review your paper and let you know the next and final steps.

Lastly, if your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

You will receive an invoice from PLOS for your publication fee after your manuscript has reached the completed accept phase. If you receive an email requesting payment before acceptance or for any other service, this may be a phishing scheme. Learn how to identify phishing emails and protect your accounts at https://explore.plos.org/phishing.

If we can help with anything else, please email us at customercare@plos.org.

Thank you for submitting your work to PLOS One and supporting open access.

Kind regards,

PLOS One Editorial Office Staff

on behalf of

Dr. Daniel F. M. Monte

Academic Editor

PLOS One

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    S1 Fig. Multiple sequence alignment of EmrD from 25 representative Escherichia coli reference strains.

    This alignment was performed using BLASTp to assess the evolutionary conservation of residues at positions 170, 173, and 304. Amino acid conservation is indicated by color coding: red denotes strictly conserved residues, while blue indicates regions of moderate to high variability. The alignment illustrates the rarity of the A173T and V304I substitutions identified in the clinical isolates of the current study.

    (RTF)

    pone.0362259.s001.rtf (74.4KB, rtf)
    S1 File. Original, uncropped agarose gel electrophoresis image for PCR amplification products.

    (PNG)

    pone.0362259.s002.png (507.7KB, png)
    S2 Fig. Multiple sequence alignment: The amino acid sequences of ten clinical E. coli isolates (DUH 01 to DUH 21) are aligned against the E. coli K-12 reference sequence (EmrD_Ref) and two prototypical uropathogenic E. coli (UPEC) reference strains: CFT073 (Accession: AAN83032.1) and 536 (Accession: WP_001335494.1).

    Asterisks (*) indicate positions with fully conserved residues; colons (:) indicate conservation between groups of strongly similar properties; and periods (.) indicate conservation between groups of weakly similar properties. Non-synonymous substitutions are highlighted by a lack of an asterisk at the corresponding position: the novel A173T in strain DUH 02 (TMH6), alongside baseline UPEC lineage-conserved features V170A in strain DUH 10 (TMH6; shared with strain CFT073)), and V304I in strains DUH 04 and DUH 10 (TMH12; shared with strains CFT073 and 536). Note: Terminal primer end-trimming restricted the analyzed clinical sequence range to residues 32–345, leaving The initial 31 amino acids for clinical isolates un-evaluated, while the core transmembrane machinery remains intact and fully aligned.

    (PDF)

    pone.0362259.s003.pdf (41.7KB, pdf)
    Attachment

    Submitted filename: Response to Reviewers.docx

    pone.0362259.s005.docx (23.6KB, docx)
    Attachment

    Submitted filename: Response_to_Reviewers_auresp_2.docx

    pone.0362259.s006.docx (19.9KB, docx)

    Data Availability Statement

    All nucleotide sequences generated for the emrD gene in this study have been deposited in the NCBI GenBank database (https://www.ncbi.nlm.nih.gov/genbank/) and are fully public. They can be accessed using the accession numbers PZ196343 through PZ196352.


    Articles from PLOS One are provided here courtesy of PLOS

    RESOURCES